Ask about this productRelated genes to: MAGEA9 antibody
- Gene:
- MAGEA9 NIH gene
- Name:
- MAGE family member A9
- Previous symbol:
- MAGE9
- Synonyms:
- MGC8421, CT1.9
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 1994-04-04
- Date modifiied:
- 2017-12-20
Related products to: MAGEA9 antibody
Related articles to: MAGEA9 antibody
- Gastrointestinal (GI) involvement in systemic sclerosis (SSc) affects up to 90% of patients and is a major driver of morbidity and mortality. Despite its clinical importance, GI disease in SSc is highly heterogeneous, with upper and lower GI manifestations representing distinct phenotypic extremes whose underlying immunologic basis remains poorly defined. - Source: PubMed
Publication date: 2026/05/21
McMahan Zsuzsanna HPuttapaka SrinivasHulett TylerShah Ami AFaheem KathrynHu ShaohuiSonmez GamzeRamos PedroKulkarni Subhash - This study aims to identify novel biomarkers for the early diagnosis of lung adenocarcinoma (LUAD), with the goal of facilitating early intervention to improve patient prognosis. - Source: PubMed
Publication date: 2026/01/05
Huang ShuyuGan YuhanZhong RuifangWang SiyingKang YanliChen JinhuaChen FalinChen LiangyuanYou Jianbin - Cancer testis antigens (CTAs) can be expressed in tumors, whereas expression is silenced in normal tissue except for the immune-privileged testis. This quasi-tumor-restricted expression makes CTAs attractive targets for T cell receptor (TCR) gene therapy. However, CTA-specific TCR gene therapy is only applicable for tumors with substantial and homogeneous CTA expression. To increase the number of patients eligible for CTA-specific TCR gene therapy, CTA expression can be upregulated with DNA-demethylating agents like 5-aza-2'-deoxycytidine (DAC). Here, we studied the effect of DAC on the recognition of a wide range of tumor cells by TCR-engineered T cells specific for the CTAs MAGE-A1, MAGE-A3/A6, or MAGE-A9. DAC treatment strongly increased expression in most tumor cell lines tested and strongly induced or improved recognition by MAGE-specific TCR-engineered T cells. However, upregulation was not limited to tumor cells but also occurred in healthy cells, resulting in MAGE-specific T cell reactivity against proliferating T and B cells. Overall, these results underscore the potential of DAC treatment to induce expression in tumor cells and to increase their sensitivity for MAGE-specific T cell therapy. However, DAC treatment can potentially result in on-target off-tumor reactivity, warranting careful consideration when using DAC as sensitizing strategy prior to adoptive transfer of CTA-specific T cells. - Source: PubMed
Publication date: 2025/07/17
de Rooij Marije A JMeeuwsen Miranda HWouters Anne KRemst Dennis F GHagedoorn Renate Svan der Steen Dirk MVerdegaal Els M EWachsmann Tassilo L AFalkenburg J H FrederikHeemskerk Mirjam H M - The expression of MAGE-A9 in vocal fold leukoplakia (VFL) tissues and the mechanism underlying its role in the malignant transformation of VFL remain unclear. This study investigated the role of MAGE-A9 in the proliferation, migration, and invasion of VFL epithelial cells as well as the underlying regulatory mechanism. - Source: PubMed
Publication date: 2025/02/19
Liu Yong-CaiYu Chun-HaiWang Qin-YingZhong Jiang-TaoBao Yang-YangFu Zi-MingChen ZheChen Heng-ChaoCao Zai-ZaiZhou Shui-Hong - Therapeutic options for synovial sarcoma (SyS) have not evolved for several decades and the efficacy of second-line treatments is very limited. The expression of a large family of proteins known as cancer testis antigens (CTAs) in SyS has spurred the development of targeted T-cell therapies currently in clinical trials, such as those aimed at melanoma-associated antigen (MAGE)-A4 and New York esophageal squamous cell carcinoma 1 (NY-ESO-1), which have shown promising clinical efficacy. Extensive knowledge of the prevalence of expression and coexpression of CTAs is critical to design T-cell therapies with optimal coverage of the patient population. We analyzed the expression of CTAs of the MAGE-A family as well as NY-ESO-1 and preferentially expressed antigen in melanoma (PRAME) by RNA sequencing in a large cohort of 133 SyS samples from patients registered in the French sarcoma database (NETSARC+). Among MAGE-As, MAGE-A4 had the highest prevalence (65%), followed by MAGE-A10 (15%) and MAGE-A9 (13%). Almost all samples (92%) expressing any of the MAGE-As also expressed MAGE-A4. NY-ESO-1 was expressed in 65% of samples, with a large but incomplete overlap with MAGE-A4, whereas PRAME was present in 121 (91%) samples. Complementary immunohistochemical analyses were used to establish the positive correlation between RNA and protein expression for MAGE-A4 and NY-ESO-1. These data inform the strategy for optimal coverage of the SyS patient population with T-cell therapies, offering patients with SyS new options for single or combined second lines of treatment. - Source: PubMed
Publication date: 2024/09/03
Vanacker HélèneConnacher RobertMeurgey AlexandraBollard JulienAttignon ValéryTirode FranckJean-Denis MyriamBrahmi MehdiBlay Jean-YvesWang RuoxiWilliams DennisDufresne Armelle